Deutsche Bank Reiterates “€93.00” Price Target for Sanofi (SAN)
Sanofi (EPA:SAN) has been assigned a €93.00 ($114.81) price target by stock analysts at Deutsche Bank in a research note issued on Thursday. The brokerage currently has a “buy” rating on the stock. Deutsche Bank’s price objective points to a potential upside of 46.71% from the company’s current price.
A number of other analysts have also recently commented on SAN. Jefferies Group set a €90.00 ($111.11) price objective on Sanofi and gave the company a “neutral” rating in a research report on Monday, October 16th. Goldman Sachs Group set a €82.00 ($101.23) price objective on Sanofi and gave the company a “neutral” rating in a research report on Tuesday, October 17th. UBS Group set a €82.00 ($101.23) price target on Sanofi and gave the stock a “neutral” rating in a research report on Monday, October 23rd. JPMorgan Chase & Co. set a €85.00 ($104.94) price target on Sanofi and gave the stock a “neutral” rating in a research report on Thursday, October 26th. Finally, Morgan Stanley set a €92.00 ($113.58) price target on Sanofi and gave the stock a “buy” rating in a research report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of €84.63 ($104.48).
Shares of Sanofi (EPA:SAN) opened at €63.39 ($78.26) on Thursday. The company has a market capitalization of $80,070.00 and a price-to-earnings ratio of 20.99. Sanofi has a 1 year low of €63.09 ($77.89) and a 1 year high of €92.97 ($114.78).
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.